Podcast brought to you by: Ingenuity Variant Analysis - Identify causal variants from human sequencing data in just hours.
. . . and by Biotix - makers of A BETTER TIP(TM) for Next Gen Sequencing
Shawn Baker, CSO, BlueSEQ Bio and Contact Info
Listen (9:29) The year of steady boring progress
Listen (4:44) PacBio has made impressive improvements
Listen (3:47) Nabsys and the gospel of long reads
Listen (4:29) Moleculo technology still unknown
Listen (4:55) Has sequencing technology reached a more stable plateau?
Listen (2:13) Illumina has a history of bumping heads with their customers
Formerly with Illumina, Shawn Baker is now CSO of BlueSEQ and a consultant on matters to do with next gen sequencing. He joins us for the second time to give an overview of the NGS industry. We caught up with Shawn just after AGBT where the industry players announce their latest and greatest.
Baker calls 2013 "the year of steady boring progress." Noting that there were not any huge breakthroughs, he says in fact there were some big promises made last year which have not been delivered on. However there has been progress, most notably by the steady improvements made to the PacBio system, and by the emergence into the field of companies such as BioNano Genomics and Nabsys focused on long read technology. What is Shawn's take on the gospel of long reads? And what does he think of the new Illumina/Moleculo technology? Join us for the State of NGS 2013.